Drugs / HL151
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03317301 | May → Nov 2017 | — | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03655210 | Feb 2017 | perennial allergic rhinitis | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HL151 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03655210 ↗ |
| Known as | Bepostatine salicylate | “HL151(1Tab,Bepostatine salicylate) once a day, 4 weeks of treatment” NCT03655210 ↗ |